FDA grants RMAT and fast track designation to cema-cel for first-line consolidation in MRD-positive LBCL

On July 29, 2026, the U.S. Food and Drug Administration (FDA) granted regenerative medicine advanced therapy (RMAT) designation and fast track designation to cemacabtagene ansegedleucel (cema-cel), an allogeneic chimeric antigen receptor T-cell therapy, for first-line consolidation therapy in patients with measurable residual disease (MRD)-positive large B-cell lymphoma who achieved complete or partial response after first-line therapy.¹

RMAT designation was based on the ALPHA3 trial (NCT06500273) interim futility analysis, in which cema-cel demonstrated MRD clearance at Day 45 of 58.3% vs 16.7% in the observation arm, with a median decrease in plasma circulating tumor DNA of 97.7% vs a 26.6% increase in the observation arm.¹ Cema-cel was well-tolerated, with no treatment-related serious adverse events, cytokine release syndrome, immune effector cell-associated neurotoxicity, graft-versus-host disease, or high-grade infections reported. Fast track designation was granted for the ALPHA3 development program.¹